307280 — Wonbiogen Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩65bn
- KR₩64bn
- KR₩30bn
- 84
- 46
- 68
- 79
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | — | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 17,721 | 26,748 | 29,615 |
Cost of Revenue | |||||
Gross Profit | — | — | 7,595 | 12,465 | 14,195 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 48.8 | 178 | 15,681 | 21,797 | 22,492 |
Operating Profit | -48.8 | -178 | 2,040 | 4,950 | 7,123 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 47.7 | -134 | -796 | 3,667 | 7,157 |
Provision for Income Taxes | |||||
Net Income After Taxes | 37.2 | -104 | -660 | 3,272 | 5,961 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 37.2 | -104 | -716 | 3,206 | 5,497 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 37.2 | -104 | -716 | 3,206 | 5,497 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 10 | -28.1 | -20.9 | 94.9 | 145 |
Dividends per Share |